Shattuck Labs said it would host an investor call and webcast on Monday to present Phase 1 clinical data for SL-325, a potential treatment for Crohn's disease, ulcerative colitis and other inflammatory and immune-mediated diseases. The presentation will include safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results, and a pipeline update, the company said. Shares rose 7.9% to $4.94 in after-hours trading.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 05, 2026 18:50 ET (22:50 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.